BOSI, COSTANZA
 Distribuzione geografica
Continente #
NA - Nord America 348
EU - Europa 227
AS - Asia 43
AF - Africa 15
Totale 633
Nazione #
US - Stati Uniti d'America 347
SE - Svezia 49
GB - Regno Unito 44
IT - Italia 32
DE - Germania 31
IE - Irlanda 18
CN - Cina 16
IN - India 12
FR - Francia 10
RU - Federazione Russa 9
TG - Togo 9
BE - Belgio 7
BG - Bulgaria 7
JO - Giordania 7
FI - Finlandia 6
CH - Svizzera 5
CI - Costa d'Avorio 5
EE - Estonia 4
UA - Ucraina 3
HK - Hong Kong 2
TW - Taiwan 2
CA - Canada 1
ES - Italia 1
LB - Libano 1
PK - Pakistan 1
PL - Polonia 1
SG - Singapore 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 633
Città #
Chandler 54
Fairfield 47
Southend 42
Ashburn 39
Dublin 18
Wilmington 18
Seattle 17
Houston 16
Woodbridge 16
Princeton 14
Ann Arbor 11
Cambridge 10
New York 10
Lomé 9
Redmond 8
Amman 7
Bremen 7
Brussels 7
Sofia 7
Berlin 6
Bologna 6
Helsinki 6
Westminster 6
Abidjan 5
Beijing 5
Bern 5
Nanjing 5
Rome 4
Saint Petersburg 4
Norwalk 3
Olalla 3
Central 2
Falls Church 2
Fiesole 2
Frankfurt am Main 2
Paris 2
San Diego 2
Taipei 2
Turin 2
Catanzaro 1
Cernusco sul Naviglio 1
Changchun 1
Chicago 1
Cutrofiano 1
Dearborn 1
Des Moines 1
Faisalabad 1
Fremont 1
Haikou 1
Hefei 1
Hounslow 1
Istanbul 1
Izhevsk 1
Jinan 1
Lissone 1
Los Angeles 1
Madrid 1
Melzo 1
Mountain View 1
Mumbai 1
Naples 1
Redwood City 1
Shenyang 1
Singapore 1
Taizhou 1
Toronto 1
Tula 1
Zelenograd 1
Totale 460
Nome #
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 130
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 126
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 116
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 99
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 71
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 67
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 47
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 4
Totale 660
Categoria #
all - tutte 2.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.212


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020156 22 1 3 11 17 15 23 23 19 10 9 3
2020/202164 14 10 1 0 1 2 2 9 12 2 5 6
2021/2022133 1 3 6 15 11 7 6 9 10 17 27 21
2022/2023205 15 30 11 22 18 19 7 14 39 4 15 11
2023/202476 4 12 8 12 10 21 0 4 0 2 0 3
Totale 660